Niraparib
BRCA1-Related Cancer Predisposition
Explore 10 assets in BRCA1-Related Cancer Predisposition →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Qian Qin
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06392841CT.gov Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations | — | Withdrawn | — | — | — |
NCT04584255CT.gov Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04030559CT.gov Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | — | Terminated | — | — | — |
NCT01905592CT.gov A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · BRCA1-Related Cancer Predisposition
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | Qian Qin | P3 | B · 63 |
| Olaparib | M.D. Anderson Cancer Center | P2 | BB |
| Rucaparib | University of Washington | P2 | B |
| Veliparib | Steven J Isakoff, MD, PhD | P2 | B |
| Durvalumab | Roswell Park Cancer Institute | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Roswell Park Cancer Institute | P2 | B |
| Pembrolizumab | Rutgers, The State University of New Jersey | P2 | CCC |
| Carboplatin | University of Washington | P2 | CCC |
| Dostarlimab | Dana-Farber Cancer Institute | P2 | CCC |
+8 more in the BRCA1-Related Cancer Predisposition cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OlaparibM.D. Anderson Cancer CenterBB
- RucaparibUniversity of WashingtonB
- VeliparibSteven J Isakoff, MD, PhDB
- DurvalumabRoswell Park Cancer InstituteB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerRoswell Park Cancer InstituteB
Citation
Floatz Terminal. Niraparib in BRCA1-Related Cancer Predisposition. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-brca1-related-cancer-predisposition
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →